Clinical research of glucocorticoid treatment in severe cases of COVID-19

doi:10.3969/j.issn.1006-7795.2020.03.005

Abstract

Abstract: Objective To evaluate the effect of glucocorticoid (GC) on severe cases of COVID-19. Methods There were 6 severe cases of diagnosed COVID-19 patients enrolled in Beijing Ditan Hospital during January 20th and February 20th in 2020.According to treatments,these patients were divided into two groups:GC group and control group. Results Compared with control group, the recovery of temperature[(2.7±1.2) d vs (6.3±0.6) d, P<0.05],oxygenation index (more than 300 mmHg,1 mmHg=0.133 kPa)[(4.6±2.1) d vs (10.6±3.1) d, P<0.05], pulmonary inflammation[(4.3±1.5) d vs (7.6±1.2) d, P<0.05] and the clinical symptoms improvement[(2.3±0.5) d vs (7.3±0.6) d, P<0.05] were earlier in GC group, and the time of oxygen inhalation was shortened[(12.1±0.8) d vs (21.7±5.7) d, P<0.05]. Conclusion Earlier use of glucocorticoid with small doses could alleviate clinical symptoms, improve their clinical courses, and promote the absorbance of infiltration in their lungs manifested in chest computed tomography(CT)for the severe cases of COVID-19.

Key words: COVID-19, severe case, glucocorticoid

CLC Number:

R563.1

Li Xingang, Xu Yanli, Wang Lin, Zhou Yang, Yang Li, Tan Dawei, Chen Zhihai, Song Rui. Clinical research of glucocorticoid treatment in severe cases of COVID-19[J]. Journal of Capital Medical University, 2020, 41(3): 345-349.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2020.03.005

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2020/V41/I3/345

References

[1] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020,395(10223):497-506.
[2] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
[3] Ahmed A E. The predictors of 3- and 30-day mortality in 660 MERS-CoV patients[J]. BMC Infect Dis,2017,17(1):615.
[4] World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected:Interim Guidance[EB/OL].(2020-01-12)[2020-03-19]. https://apps.who.int/iris/handle/10665/330893.
[5] 国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-19)[2020-03-18].http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.Shtml
[6] 国家卫生健康委员会办公厅,国家中医药管理局办公室.新型冠状病毒肺炎重型、危重型病例诊疗方案(试行第二版)[EB/OL].(2020-02-14)[2020-3-18].http://www.nhc.gov.cn/yzygj/s7653p/202004/c083f2b0e7eb4036a59be419374ea89a.shtml.
[7] 李威,柳德兵.甲泼尼龙琥珀酸钠治疗新型冠状病毒肺炎的有效窗口期[J/OL].武汉大学学报(医学版).(2020-03-23)[2020-03-24].https://doi.org/10.14188/j.1671-8852.2020.0168.
[8] 陈倩,裴茂华,王瑶,等.糖皮质激素在新型冠状病毒肺炎中应用的利与弊[J/OL].武汉大学学报(医学版):(2020-03-09)[2020-03-24].https://doi.org/10.14188/j.1671-8852.2020.0136.
[9] 连玉菲,刘洪涛,高海祥,等.奥司他韦联合痰热清注射液治疗小儿病毒性肺炎的效果及安全性[J].解放军医药杂志,2018,30(12):48-52.
[10] Stern A, Skalsky K, Avni T,et al. Corticosteroids for pneumonia[J]. Cochrane Database Syst Rev, 2017, 12(12):CD007720.
[11] Russell C D, Millar J E, Baillie J K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury[J]. Lancet, 2020,395(10223):473-475.
[12] Wong C K, Lam C W, Wu A K, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome[J].Clin Exp Immunol, 2004,136(1):95-103.
[13] 董红建,谭捷.糖皮质激素联合参芪扶正注射液辅治重症社区获得性肺炎致ARDS患者效果观察及对血清炎性因子、血气指标影响[J].临床误诊误治,2019,32(11):25-29.
[14] Falsey A R, Walsh E E. Novel coronavirus and severe acute respiratory syndrome[J]. Lancet, 2003, 361(9366):1312-1313.
[15] Wan S X, Yi Q J, Fan S B, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP)[J/OL]. Medrxiv.(2020-2-12)[2020-03-20].https://www.medrxiv.org/content/10.1101/2020.02.10.20021832v1.
[16] Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020,8(4):420-422.
[17] Auyeung T W, Lee J S, Lai W K, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes:a retrospective cohort study[J]. J Infect,2005, 51(2):98-102.
[18] Chen S, Wu J J, Li Z M, et al. Clinical features of 109 cases of novel coronavirus pneumonia[J/OL]. Chin J Infect Dis.(2020-02-27)[2020-3-19].http://rs.yiigle.com/yufabiao/1186991.htm.
[19] Wu C, Chen X, Cai Y, et al. Risk factors associated with qcute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China[J]. JAMA Intern Med.(2020-03-13)[2020-03-19].https://jamanetwork.com/journals/jamain ternalmedicine/fullarticle/2763184.doi:10.1001/jamainternmed.2020.0994.
[20] Zhou W, Liu Y, Tian D, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia[J]. Signal Transduct Target Ther, 2020,5(1):18.